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ABSTRACT
Background  Treatment with tumour necrosis factor 
inhibitors (TNF-i) plus methotrexate (MTX), but 
not MTX monotherapy alone, inhibits joint damage 
progression even at higher levels of disease activity. 
Such disassociation of disease activity and structural 
damage has not been shown for biological agents other 
than TNF-i.
Objectives  To evaluate whether interleukin 6 (IL-6) 
inhibition with tocilizumab (TCZ) interferes with joint 
destruction beyond its effects on disease activity.
Methods  A random 90% sample of data from the (The 
Tocilizumab Safety and the Prevention of Structural Joint 
Damage Study) LITHE trial on active rheumatoid arthritis 
(RA) despite MTX was used, which compared addition 
of placebo (n=117) with addition of TCZ (n=414) every 
4 weeks. Baseline and 1-year values of clinical and 
serological variables were correlated with changes to 
1 year of the total Genant-modiﬁ  ed Sharp score (TGSS) 
using a Spearman test, and the progression of TGSS, 
erosion and joint space narrowing (JSN) scores in groups 
with low and high disease activity were compared for 
placebo and TCZ (Kruskal–Wallis).
Results  Baseline variables were similar among 
the groups. Change of TGSS was lower in patients 
receiving TCZ than placebo (TCZ: 0.29±0.96; placebo: 
0.90±1.92; p=0.0007). In patients receiving placebo, 
the correlation with TGSS change was signiﬁ  cant for 
baseline scores of the simpliﬁ  ed disease activity index 
(SDAI; r=0.18, p=0.047) and swollen joint count 28 
(r=0.22, p=0.019), with similar trends for C-reactive 
protein. Similar correlations were seen for SDAI, clinical 
disease activity index, disease activity score 28 at 1 
year with x-ray change during that year (r=0.26–0.28, 
p=0.002–0.006). In contrast, none of the baseline 
or 1-year variables showed signiﬁ  cant correlation 
with x-ray changes in patients receiving TCZ+MTX, 
suggesting a disassociation of the link between disease 
activity and damage by TCZ. Finally, for patients in 
remission or with low disease activity, progression of 
TGSS, erosion and JSN was similar among treatment 
groups (TGSS: placebo, 0.4±1.1; TCZ, 0.2±0.7; 
p=NS), while for patients with moderate or high 
disease activity placebo-treated patients progression 
was signiﬁ  cantly greater (TGSS: 1.2±2.2 vs 0.4±1.2; 
p=0.0009).
Conclusions  IL-6 inhibition with TCZ plus MTX retards 
joint damage progression independently of its impact 
on disease activity. Similar effects have hitherto been 
reported only for TNF-i. This indicates that the effects of 
IL-6 inhibition on progression of joint damage in RA are 
among the most profound currently attainable.
INTRODUCTION
It is well established that the extent and pro-
gression of joint damage in rheumatoid arthri-
tis (RA) is primarily related to the degree of the 
inﬂ   ammatory process as depicted especially by 
joint swelling and the acute phase response, and 
also by levels of composite measures of disease 
activity.1–6 The correlation between inﬂ  ammation 
and joint destruction has been recently even fur-
ther accentuated by the observation that progres-
sion of damage occurs mostly in joints which are 
swollen and that joint swelling may contribute 
more strongly to progression of destruction than 
the acute phase response.7 8 All these relationships 
concern both the natural course of RA and patients 
treated with synthetic disease-modifying agents. 
Therefore, the observation made several years 
ago that tumour necrosis factor (TNF)-inhibitors 
in combination with methotrexate (MTX) can halt 
progression of radiographic joint destruction even 
in patients who continue to have active disease 
was somewhat surprising.6 9–11 However, hitherto 
similar observations have not been made with 
other biological agents.
While TNF is a pivotal cytokine in RA,12 other 
cytokines, such as interleukin (IL)-6 also appear to 
be importantly involved in the pathogenesis of the 
disease.13 Indeed, IL-6 activates a whole cascade 
of events characteristic of inﬂ  ammation, and leads 
to metalloproteinase-mediated degradation of 
cartilage matrix and activation of osteoclasts.14–17 
Tocilizumab (TCZ), an anti-IL-6-receptor antibody, 
was recently shown to be efﬁ  cacious in the treat-
ment of RA. Its efﬁ  cacy includes reduction in signs 
and symptoms, improvement of physical function 
and inhibition of joint damage progression.18–21 
However, it is not known if the effect of TCZ on 
joint damage is directly related to the reduction 
of signs and symptoms of inﬂ  ammatory disease 
activity or if, similarly to the aforementioned 
observations on TNF-inhibitors, IL-6 blockade can 
interfere with joint destruction beyond its effect 
on synovitis. Examining this question is the focus 
of this study.
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there was no signiﬁ  cant difference in clinical variables between 
patients who had complete datasets and those whose data were 
incomplete; for example, in the overall population among those 
who were selected compared with those having missing data-
sets, the mean swollen joint counts 28 (SJC28) were 12.0 versus 
12.0, TJC28 were 15. 3 versus 15.8, mean DAS28 was 6.5 versus 
6.6, mean CDAI 39.5 versus 40.6 and mean HAQ was 1.5 in 
both groups, indicating that there was no selection bias.
Analyses
We assessed progression of radiological damage in the placebo 
and active treatment arms by calculating the difference between 
the 1-year and baseline scores (∆TGSS). We partly pooled 
patients of the 4 and 8 mg/kg treatment arms, since inhibition 
of joint damage was similar in these two groups and to increase 
the sample size and thus the statistical power of this post hoc 
completer analysis.21 We correlated the change in joint damage 
with baseline and 1-year values of the core set variables (see 
above) and the three composite measures of disease activity. In 
additional analyses we focused on patients who experienced 
progression of joint damage (∆TGSS>0.25) in the placebo and 
active treatment groups and assessed the relationship of the dif-
ferent baseline variables with progress or status using a multi-
variate logistic regression model.
Based on the SDAI at 1 year, we then dichotomised patients 
into those who attained remission or LDA and those who 
remained in MDA or HDA, and compared the changes in radio-
graphic scores between these two groups. In a sensitivity anal-
ysis we compared the progression of joint damage in patients 
who achieved a normal C-reactive protein (CRP) (≤0.3 mg/dl) 
at 1 year with those who did not, as well as in patients who 
achieved an SJC≤1 with those who did not.
Statistical analyses were done using R software.26 Correlations 
between individual variables and progression of joint damage 
were assessed using Spearman correlation; differences between 
groups were evaluated by Kruskal–Wallis test. In addition, a 
multivariate logistic regression model was applied. p Values 




We were kindly provided by the trial sponsor a 90% ran-
dom sample of patient level data from the LITHE clinical 
trial on patients with active RA despite MTX treatment,21 
in which signs and symptoms as well as x-ray ﬁ  ndings were 
evaluated.
The data included the traditional clinical variables, such as 
swollen and tender joint counts (SJC, TJC), patient’s and phy-
sician’s global assessments and patient’s pain assessments, 
acute phase reactant (APR) levels, and the Health Assessment 
Questionnaire disability index (HAQ). Radiographs had been 
assessed at baseline and 1 year using the total Genant-modiﬁ  ed 
Sharp score (TGSS)22 by two independent readers blinded to 
treatment assignment, chronological order of radiographs and 
patients’ clinical responses; this method evaluates hands and 
feet separately for joint space narrowing (JSN) and erosions with 
a maximal total score of 200, which is about half as large as the 
modiﬁ  ed Sharp score and somewhat less than half of the van der 
Heijde modiﬁ  ed (vdH-) Sharp score.23 Given that the increments 
in the TGSS are based on steps of 0.5 and x-ray ﬁ  ndings were 
assessed by two readers, in line with previous considerations24 
progression of joint damage may be regarded as an average 
score of ≥0.25.
For correlations with joint involvement, we used both the 
66/68 and 28-joint counts. We also calculated the disease activ-
ity score employing 28 joint count (DAS28) and erythrocyte 
sedimentation rate (ESR), the simpliﬁ   ed and clinical disease 
activity indices (SDAI, CDAI) as well as disease activity states, 
remission, low, moderate and high disease activity (LDA, MDA, 
HDA) using the respective established formulae and cut-off 
points.25
We excluded from further assessment all patients with 
incomplete data needed for these analyses, which required 
the availability of clinical and radiographic data at baseline 
and 12 months; a total of 531 patients fulﬁ  lled these criteria. 
These patients had randomly received placebo (n=117), TCZ at 
4 mg/kg (n=197), or TCZ at 8 mg/kg (n=217) every 4 weeks 
in addition to their insufﬁ  ciently effective MTX. Importantly, 
Table 1  Characteristics of patients in the placebo arm and the pooled treatment arms of tocilizumab, at 
baseline and after 1 year (mean±SD, unless indicated otherwise)
Baseline (BL) 1 Year
Characteristics BL PL BL TCZ 1-yr PL 1-yr TCZ
N 117 414 117 414
Age (years) 50.3±12.3 52.5±11.5 - -
Disease duration (years) 8.57±8.5 8.85±7.8 - -
Rheumatoid factor (% positive) 83.7 81.8 - -
Swollen joint count (0–28) 11.4±5.0 12.2±5.6 4.4±4.7 3.3±3.4**
Tender joint count (0–28) 14.2±6.4 15.5±6.6* 5.7±5.7 4.0±5.2***
Patient global (0–100 mm) 61.3±22.0 59.8±23.3 37.5±23.2 31.4±23.5**
Evaluator global (0–100 mm) 59.0±17.7 62.5±16.1* 24.4±17.6 18.8±16.6**
Pain (0–100 mm) 52.1±21.6 53.2±22.7 33.3±20.5 28.7±21.9**
C-reactive protein (mg/dl) 2.0±2.3 2.3±2.6 1.4±1.7 0.5±1.2***
Erythrocyte sedimentation rate (mm/h) 44.4±23.5 46.4±24.9 33.8±22.0 13.5±15.8***
Disease activity score 28 (DAS28) 6.3±0.8 6.5±0.9* 4.2±1.3 2.9±1.4***
Simpliﬁ  ed disease activity index (SDAI) 39.6±12.0 42.3±13.2* 17.7±12.0 12.8±10.3***
Clinical disease activity index (CDAI) 37.6±11.3 40.0±12.4 16.3±11.3 12.3±10.0***
Health Assessment Questionnaire (HAQ) 1.5±0.6 1.5±0.6 1.0±0.6 0.9±0.6
Genant-modiﬁ  ed total Sharp score (TGSS) 27.1±28.3 27.1±26.5 28.0±28.5 27.4±26.7
Change in TGSS NA NA 0.90±1.92 0.29±0.96+
*p<0.05, **p<0.01, ***p<0.001 (p values comparing the two baseline or 1-year treatment groups); +p<0.001 for comparison of 
PL with TCZ treatment; NA, not applicable.
PL, placebo; TCZ, tocilizumab.
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When the area under the curve (AUC) of the predictive vari-
ables over 1 year was used instead of their baseline in placebo-
treated patients, again particularly CRP, SJC28, TJC28, SDAI, 
CDAI and DAS28 were signiﬁ   cantly correlated with radio-
graphic progression (r=0.15–0.33), conﬁ  rming the results shown 
above. In a multivariate logistic model using the AUC of CRP, 
ESR, SJC and TJC, only CRP was signiﬁ  cantly associated with 
radiographic progression (p=0.002). In line with the lack of sig-
niﬁ  cant association in the univariate analyses, the logistic model 
for patients treated with TCZ did not show any signiﬁ  cant 
results, including for CRP-AUC.
RESULTS
Outcomes in the different treatment groups
Demographic and baseline as well as 1-year RA-related data of 
the patients studied are shown in table 1. There were slightly 
higher TJC, evaluator global assessment (EGA), DAS28 and 
SDAI values for the TCZ group than for placebo, but these dif-
ferences were small (mostly <10%), in contrast to the 1-year 
results which showed signiﬁ   cant differences between treat-
ment groups for all clinical variables. In line with the published 
data,21 also in the dataset analysed here the change of TGSS 
score was signiﬁ  cantly higher in patients receiving placebo than 
those treated with TCZ (placebo: 0.90±1.92, TCZ: 0.29±0.96, 
p=0.0007). It should be noted that the overall change in x-ray 
score, even in placebo-treated patients, was very low; this is 
primarily due to the scoring method, since—as discussed 
above—the TGSS, in contrast to the modiﬁ  ed Sharp and van 
der Heijde modiﬁ  ed Sharp score, has a smaller range,23 25 27 but 
possibly also due to a trend towards lower progression of joint 
damage observed over the past decade.28 Even when consider-
ing only patients who progressed, the mean change in TGSS 
was relatively low (placebo: 2.6±2.5, TCZ: 1.5±1.5, p=0.012), 
thus reducing the overall signal for the associative radiographic 
analyses.
Correlation of characteristics at baseline and 1 year with 
progression of joint damage
In the placebo arm, the correlation analysis with progression of 
TGSS was signiﬁ  cant for baseline SDAI (r=0.18, p=0.047) and 
baseline SJC28 (r=0.22, p=0.019); a similar trend was seen for 
baseline CRP (r=0.15, p=0.106) and baseline CDAI (r=0.174, 
p=0.061). Using a full joint count did not result in a better cor-
relation for swollen or tender joint counts (not shown). Similar 
results were also observed when correlating disease activity at 1 
year (instead of baseline) with x-ray progression during that year 
for SDAI, CDAI and DAS28 (r=0.26-0.28, p=0.002 to p=0.006), 
with individual variables also showing signiﬁ  cant associations 
or at least trends (data not shown in detail). In contrast, in 
patients treated with TCZ, none of the baseline or 1 year vari-
ables showed signiﬁ  cant correlation with x-ray progression (for 
example, at 1 year, CRP: r=0.08; SJC28: r=0.007; SDAI: r=0.005; 
all p values NS).
Table 2  Values (mean±SD) of composite disease activity measures (CDAI, SDAI, DAS28) at baseline and 1 year, and progression of total joint 
damage score (change in TGSS), ERO and JSN in the patients with moderate/high disease activity according to the respective cut-off points at 1 year 
of treatment. The data are shown separately for placebo and for the combined tocilizumab (TCZ) groups and for the two TCZ doses. Differences were 
assessed by Kruskal–Wallis test (for median values of x-ray changes see text). According to established cut-off points, patients were regarded as in 




Tocilizumab 4 mg 
(97/197)
Tocilizumab 8 mg 
(100/217)




p Value vs 
placebo
Baseline values
CDAI 40.5±10.8 41.72±12.13 45.42±12.74 0.0103 43.6±12.6 0.048
SDAI 42.5±11.4 44.04±12.76 48.17±13.93 0.0105 46.1±13.5 0.04
DAS28 6.5±0.7 6.70± 0.9 6.95±0.87 0.0023 6.8±0.9 0.008
HAQ 1.61±0.61 1.56±0.58 1.64±0.63 0.566 1.60±0.60 0.78
1-Year values
CDAI 21.7±10.4 19.34±9.26 20.96±9.36 0.12 20.2±9.3 0.19
SDAI 23.4±11.2 20.69±9.40 21.16±9.36 0.13 20.9±9.3 0.053
DAS28 4.9±1.1 4.22±1.12 3.64±1.03 <0.0001 3.9±1.1 <0.0001
HAQ 1.31±0.63 1.22±0.59 1.18±0.63 0.45 1.20±0.61 0.237
Change in TGSS at 1 year 1.2±2.2 0.40±1.10 0.40±1.20 0.0038 0.4±1.2 0.0009
Change in ERO at 1 year 0.65±1.26 0.28±0.86 0.23±0.88 0.0247 0.25±0.87 0.00651
Change in JSN at 1 year 0.53±1.21 0.12±0.47 0.17±0.55 0.0154 0.14±0.51 0.00435
CDAI, clinical disease activity index; DAS28, disease activity score 28; ERO, erosion; HAQ, Health Assessment Questionnaire; HDA, high disease activity; JSN, joint space narrowing 
score; MDA, moderate disease activity; SDAI, simpliﬁ  ed disease activity index; TGSS, total Genant-modiﬁ  ed Sharp score.
Figure 1  Mean change from baseline to 1 year of the total Genant-
modiﬁ  ed Sharp score (TGSS) among patients in low disease activity 
states (low disease activity or remission) and high disease activity 
states (moderate or high disease activity) after exposure to placebo 
(plus methotrexate (MTX)), tocilizumab (TCZ) at 4 mg/kg and/or 8 mg/
kg (plus MTX). The differences in TGSS between low and high disease 
activity status were signiﬁ  cant for placebo (p=0.0009), but generally 
low and not signiﬁ  cant for the TCZ-treated group, irrespective of the 
dose and disease activity status.
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Progression of joint damage in high and low 
disease activity states
Next, we investigated the subgroups of patients who achieved 
remission or LDA, or had MDA/HDA. In the placebo group 
(with background MTX), 35% of the patients attained remission 
or LDA by SDAI at 1 year, while 65% were in MDA or HDA. 
Among patients treated with TCZ plus MTX, 52% attained the 
lower and 48% had MDA/HDA after 1 year. The baseline and 
endpoint scores of composite disease activity (CDAI, SDAI) and 
functional measures of patients with MDA/HDA are shown in 
table 2. Given their relative similarity (±10%) when compar-
ing placebo with TCZ-treated patients, differences in disease 
activity are unlikely to explain the observed threefold difference 
in radiographic progression (mean change 1.2±2.2 for placebo 
and 0.4±1.2 for TCZ, p=0.0009 by Kruskal–Wallis test; ﬁ  gure 1, 
Taken together, these data suggested that the link between 
surrogate markers of disease activity and progression of joint 
damage could be seen in placebo-treated patients also when the 
TGSS was employed, but that TCZ treatment abrogates this 
association between disease activity and destruction, similar to 
previous reports for TNF inhibitors.2 9 10 29
In a further sensitivity analysis, we also tested patients cat-
egorised into LDA and HDA by SDAI who had sustained this 
status for at least the last two consecutive visits. Interestingly, 
of the 258 patients with LDA at the end point, 206 (80%) had 
sustained this state and, likewise, persistent HDA was seen in 
221 (81%) of the 273 patients categorised as having HDA at the 
end point. Importantly, results similar to the above radiographic 
data were seen in those patients who had sustained these states 
(not shown).
Table 3  SJC28, CRP and change in TGSS in patients who attained normal CRP (CRP≤0.3 mg/dl) at 1 year or 
not. Data are shown as mean±SD for the three treatment arms. p Values denote differences among treatment 
groups (Kruskal–Wallis test)
  CRP≤0.3 mg/dl CRP>0.3 mg/dl
Treatment n SJC28 CRP ∆TGSS n SJC28 CRP ∆TGSS
Placebo 19 2.8±2.9 0.15±0.08 0.3±0.6 98 4.7±5.0 1.6±1.8 1.0±2.1
TCZ 4 81 3.1±3.8 0.12±0.09 0.4±1.2 116 3.4±4.0 1.5±1.9 0.2±0.8
TCZ 8 199 3.3±3.9 0.05±0.05 0.3±1.0 18 3.0±3.6 1.3±1.4 0.3±0.9
p Value   0.979 0.0001 0.449   0.069 0.471 0.015
CRP, C-reactive protein; SJC28, swollen joint count 28; TGSS, Genant-modiﬁ  ed total Sharp score; TJC28, tender joint count 28, 
TCZ, tocilkizumab.
Figure 2  Change from baseline to 1 year of radiographic score in (A) patients with normal C-reactive protein (CRP; ≤0.3 mg/dl) at 1 year and 
(B) patients with raised CRP (>0.3 mg/dl) at 1 year treated with either placebo or tocilizumab (TCZ) at 4 mg/kg or 8 mg/kg.
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between the treatment groups (6.3±4.7, 5.5±3.9 and 5.5±3.8 for 
the placebo, 4 and 8 mg/kg groups, p=0.578).
All these data further support the above observation that TCZ 
plus MTX reduces progression of, and almost halts, joint dam-
age even in patients who continue to have active disease. This 
ﬁ  nding is bolstered by revealing similar effects of both TCZ 
doses studied, despite the fact that the TCZ 4 mg/kg group had 
more patients with active disease.21
DISCUSSION
The data presented indicate that TCZ plus MTX removes 
the usual correlation between disease activity and joint dam-
age. This conclusion is based on the ﬁ  nding that in patients 
for whom MTX produced an insufﬁ  cient response, treatment 
with TCZ led to a signiﬁ  cant reduction in the progression of the 
radiographic score compared with patients receiving placebo, 
even if these patients had MDA or HDA by composite disease 
activity score assessment or their CRP or SJC had failed to nor-
malise. Indeed, the progression of joint damage in these patients 
did not exceed that of patients treated with TCZ plus MTX who 
attained low disease activity or remission, or whose CRP or SJC 
had normalised.
Patients in the placebo group had a low progression of the 
radiographic score only in LDA states, but not at higher disease 
activity. In contrast, patients treated with TCZ plus MTX had 
only small changes in joint damage whether they were in LDA 
or HDA states. Similar ﬁ  ndings were obtained with the lower 
and clinically less effective TCZ dose as with the higher TCZ 
dose. Moreover, the disassociating effect of TCZ pertained to 
both bone erosions and cartilage damage, thus affecting the 
pathogenesis of RA joint destruction in its totality.
The correlation between disease activity and joint damage 
has hitherto been shown for the Sharp and vdH–Sharp as well 
as the Larsen score.2 4 5 32 Here we have expanded these obser-
vations to the Genant-modiﬁ  ed Sharp score. This score has no 
known advantages over the Sharp or vdH–Sharp scores, but it 
has been validated and used in several recent trials.33–36 The 
scale of the TGSS is smaller than that of the other scores25 27 
and the progression of joint damage in this study was quite low 
as a consequence of this fact and/or the observation of reduced 
progression of joint damage in recently studied patients with 
RA.28 Presumably, owing to the low progression rate, the cor-
relation between individual disease activity measures and TGSS 
progression was mainly conﬁ  ned to CRP levels. Importantly, 
however, a similar correlation was seen between progression 
of joint damage and composite measures. This comprised the 
CDAI which does not contain an APR, showing that other fac-
tors than just APRs contribute to damage, as has been previously 
shown for other radiographic scores.1 4 5 Composite scores have 
the advantage of capturing a larger spectrum of disease activity 
than single variables, given that their preponderance can vary 
between, and even within, individual patients.25 37 38
One of the limitations of our study is that it was a post hoc 
analysis rather than a prospective study. Therefore, the results 
from the comparisons of the placebo and TCZ groups, and the 
association of diseases activity with progression, can only be 
hypothesis generating. On the other hand, the data had been pro-
spectively obtained, and are in line with previous observations 
in patients treated with TNF blockers, which all were likewise 
post hoc assessments.10 11 39 In this sense, our study expands for 
the ﬁ  rst time the concept to another mode of action—namely, 
IL6 inhibition. Another limitation is the focus on completers, 
but having complete data, especially for radiographic outcomes, 
is a prerequisite of the study and most correlations with joint 
table 2). The ﬁ  nding that DAS28 values at 1 year were highly 
discordant between the two treatment groups is a consequence 
of the profound effect of TCZ on the APR, such as ESR, which is 
overweighted in the DAS28 formula.30 31 The APR, CRP, is much 
less weighted in the SDAI and not included at all in the CDAI 
and, therefore, the differences between the treatment groups of 
both indices are much smaller and not signiﬁ  cant for patients 
achieving only MDA/HDA at 1 year; a similar observation was 
made for the HAQ and likewise when the TCZ group was sepa-
rated into the 4 and 8 mg/kg subgroups.
While also among patients attaining remission or LDA, 
numerically slightly higher progression scores were seen in pla-
cebo-treated patients than in those treated with TCZ (means: 
0.4±1.1 vs 0.2±0.7, ﬁ  gure 1), these differences were not signiﬁ  -
cant. Importantly, however, in patients receiving placebo the 
difference in progression of joint damage was signiﬁ  cant when 
comparing those attaining remission or LDA with those achiev-
ing MDA or HDA at 1 year (n=117; p=0.011), while in the TCZ 
group this difference was not signiﬁ  cant (n=414; p=0.161, ﬁ  g-
ure 1). Similar data were observed when comparing each of the 
two TCZ dose groups separately with the placebo group. These 
data further suggested that TCZ plus MTX interferes with pro-
gression of joint damage even in patients who continue to have 
active disease.
Progression of joint space narrowing and erosions
The TGSS comprises the erosion and the JSN score. As shown 
in table 2, the inhibition by TCZ of joint damage progression 
even in the presence of active disease affected JSN and erosions 
in a similar way. This ﬁ  nding indicates that TCZ interferes 
independent of disease activity with both osteoclastogenic 
and cartilage-degrading pathways. This conclusion is further 
strengthened by similar ﬁ  ndings for the higher and lower TCZ 
dose (table 2).
Inﬂ  uence of high CRP or high SJC at 1 year
In a sensitivity analysis, we dichotomised patients in the placebo 
and TCZ groups into those who had normalised their CRP and 
those who had not, and assessed progression of joint damage in 
these patients; in this analysis we evaluated the two tocilizumab 
groups separately, because it had been established that CRP nor-
malises less frequently at 4 mg/kg than 8 mg/kg.18 21
Among patients with normal CRP at 1 year, the SJCs in those 
treated with placebo or TCZ were similar (table 3); likewise the 
progression of joint damage was very similar among all three 
treatment arms (table 3, ﬁ  gure 2A). The numerically small, but 
statistically signiﬁ  cant difference in CRP levels did therefore not 
seem to inﬂ  uence progression at this low level.
In contrast, among patients who did not attain normal CRP 
at 1 year, signiﬁ   cantly less progression of joint damage was 
seen in those receiving TCZ 4 mg/kg (0.24±0.78) and 8 mg/kg 
TCZ (0.34±0.88) than in patients receiving placebo (1.03±2.07; 
p=0.015; ﬁ  gure 2B); mean CRP levels were almost identical in 
all three groups. However, since the SJC was numerically lower 
in patients treated with TCZ (p=0.07, Kruskal–Wallis test; table 
3) and since progression of joint damage at low disease activ-
ity appears to be linked to SJC rather than CRP,8 we performed 
an additional analysis looking at patients who did not attain a 
normal SJC (SJC>1).
Indeed, patients who had SJC>1 at 1 year showed signiﬁ  cantly 
less progression of joint damage upon treatment with TCZ 
(0.4±1.2 in the 4 mg/kg and 0.3±1.0 in the 8 mg/kg arm) com-
pared with placebo (0.9±1.8; p=0.009); SJC were quite similar 
11_annrheumdis-2011-200395.indd   691 11_annrheumdis-2011-200395.indd   691 3/30/2012   8:40:15 PM 3/30/2012   8:40:15 PMClinical and epidemiological research
Ann Rheum Dis 2012;71:687–693. doi:10.1136/annrheumdis-2011-200395 692
 3.  Dawes PT, Fowler PD, Clarke S, et al. Rheumatoid arthritis: treatment which controls 
the C-reactive protein and erythrocyte sedimentation rate reduces radiological 
progression. Br J Rheumatol 1986;25:44–9.
 4.  Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite 
disease activity indices for rheumatoid arthritis: validation of a clinical activity score. 
Arthritis Res Ther 2005;7:R796–806.
 5.  van der Heijde DM, van Riel PL, van Leeuwen MA, et al. Prognostic factors for 
radiographic damage and physical disability in early rheumatoid arthritis. A prospective 
follow-up study of 147 patients. Br J Rheumatol 1992;31:519–25.
 6.  Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid 
arthritis patients attaining different disease activity states with methotrexate 
monotherapy and inﬂ  iximab plus methotrexate: the impacts of remission and tumour 
necrosis factor blockade. Ann Rheum Dis 2009;68:823–7.
 7.  Klarenbeek NB, Güler-Yüksel M, van der Heijde DM, et al. Clinical synovitis in a 
particular joint is associated with progression of erosions and joint space narrowing 
in that same joint, but not in patients initially treated with inﬂ  iximab. Ann Rheum Dis 
2010;69:2107–13.
 8.  Aletaha D, Smolen JS. Rheumatoid arthritis near remission: clinical rather than 
laboratory inﬂ  ammation is associated with radiographic progression. Ann Rheum Dis 
2011;70:1975–80. Epub 2011 Jul 28.
 9.  Smolen JS, Han C, Bala M, et al. Evidence of radiographic beneﬁ  t of treatment 
with inﬂ  iximab plus methotrexate in rheumatoid arthritis patients who had no 
clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis 
factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 
2005;52:1020–30.
10.  Landewé R, van der Heijde D, Klareskog L, et al. Disconnect between inﬂ  ammation 
and joint destruction after treatment with etanercept plus methotrexate: results from 
the trial of etanercept and methotrexate with radiographic and patient outcomes. 
Arthritis Rheum 2006;54:3119–25.
11.  Emery P, Genovese MC, van Vollenhoven R, et al. Less radiographic progression 
with adalimumab plus methotrexate versus methotrexate monotherapy across 
the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 
2009;36:1429–41.
12.  Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in 
pathophysiology and therapeutics. Immunol Rev 2008;223:7–19.
13.  Fonseca JE, Santos MJ, Canhão H, et al. Interleukin-6 as a key player in systemic 
inﬂ  ammation and joint destruction. Autoimmun Rev 2009;8:538–42.
14.  Rose-John S, Scheller J, Elson G, et al. Interleukin-6 biology is coordinated by 
membrane-bound and soluble receptors: role in inﬂ  ammation and cancer. 
J Leukoc Biol 2006;80:227–36.
15.  Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble interleukin-6 receptors in 
the synovial ﬂ  uids from rheumatoid arthritis patients are responsible for osteoclast-like 
cell formation. J Bone Miner Res 1996;11:88–95.
16.  Kudo O, Sabokbar A, Pocock A, et al. Interleukin-6 and interleukin-11 support human 
osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1–7.
17.  Legendre F, Bogdanowicz P, Boumediene K, et al. Role of interleukin 6 (IL-6)/IL-6R-
induced signal tranducers and activators of transcription and mitogen-activated 
protein kinase/extracellular. J Rheumatol 2005;32:1307–16.
18.  Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor 
inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): 
a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97.
19.  Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus 
methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: 
the AMBITION study. Ann Rheum Dis 2010;69:88–96.
20.  Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves 
treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour 
necrosis factor biologicals: results from a 24-week multicentre randomised placebo-
controlled trial. Ann Rheum Dis 2008;67:1516–23.
21.  Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage 
in rheumatoid arthritis patients with inadequate responses to methotrexate: results 
from the double-blind treatment phase of a randomized placebo-controlled trial of 
tocilizumab safety and prevention of structural joint damage at one year. 
Arthritis Rheum 2011;63:609–21.
22.  Genant HK, Jiang Y, Peterfy C, et al. Assessment of rheumatoid arthritis using 
a modiﬁ  ed scoring method on digitized and original radiographs. Arthritis Rheum 
1998;41:1583–90.
23.  van der Heijde D. How to read radiographs according to the Sharp/van der Heijde 
method. J Rheumatol 1999;26:743–5.
24.  van der Heijde D, Simon L, Smolen J, et al. How to report radiographic data 
in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable 
discussion. Arthritis Rheum 2002;47:215–8.
25.  Aletaha D, Smolen JS. The deﬁ  nition and measurement of disease modiﬁ  cation in 
inﬂ  ammatory rheumatic diseases. Rheum Dis Clin North Am 2006;32:9–44, vii.
26.  R Development Core Team. A language and environment for statistical computing. 
R Foundation for Statistical Computing, Vienna, Austria ISBN 3-900051-07-0. http://
www.R-project.org. 2010 (accessed 30 June 2011).
27.  Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. 
Am J Med 1983;75(6A):35–47.
damage observed related to baseline and to 1-year clinical ﬁ  nd-
ings; moreover, the selected patients did not differ signiﬁ  cantly 
from those without complete data. The most provoking limita-
tion, though was the small signal observed with the Genant-
modiﬁ  ed Sharp score. As discussed above, it was satisfying that 
despite this major limitation within the dataset a correlation 
between a change in the score and CRP as well as composite 
measures of disease activity was seen in the control group, as 
this has been seen for placebo or MTX with other scores.6 10 11 39 
This correlation was abrogated and progression of joint damage 
was minimal upon TCZ plus MTX treatment, which together 
with several sensitivity analyses supports the suggestion of the 
disassociating effects of IL-6 pathway inhibition.
IL-6 activates the cascade of inﬂ  ammatory events17 40 41 and 
directly ampliﬁ  es osteoclastogenesis,15 42 as does TNF.43–46 Thus, 
inhibition of IL-6 activity as induced by TCZ can impede both 
cartilage and bony damage, as shown in studies assessing joint 
destruction or cartilage and bone breakdown products,21 47 and 
interferes with the important link between disease activity (ie, 
process) and damage (ie, outcome). This has an impact also on 
clinical non-responders to TCZ, because they will not experi-
ence signiﬁ  cant progression of joint damage, which is in contrast 
to patients continuing MTX despite an insufﬁ  cient response, or 
to patients receiving de novo MTX who do not attain remis-
sion.6 9 10 Nevertheless, the residual disease activity will still 
affect their physical function and quality of life and, therefore, 
as for non-responders to other treatments including TNF block-
ers, these patients will require a change of treatment.
An explanation for the disassociating effect of TNF inhibition 
has been proposed by hypothesising that activation of osteo-
clasts may require a higher threshold for TNF effects than the 
expression of signs and symptoms of inﬂ  ammation.48 The same 
explanation may be valid for IL-6 blockade, but this will have to 
be further tested experimentally. Whether a similar effect can 
be seen with TCZ monotherapy, which also inhibits progres-
sion of joint damage,49 will have to be studied using respective 
data. Likewise, to determine whether this effect is speciﬁ  c to 
IL-6 receptors and TNF inhibition or a more general quality of 
biological agents, similar studies in rituximab and abatacept 
databases will have to be performed.
In conclusion, IL-6 receptor inhibition with TCZ, in combina-
tion with MTX, entails inhibition of joint damage even in higher 
disease activity states. This suggests that interference with the IL-6 
pathway will achieve the same level of anti-destructive effects as 
has previously been reported only for several TNF inhibitors.
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